Ken Griffin Chimerix Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.77 - $1.07 $10,934 - $15,194	-14,200 Reduced 29.52%	33,900 $31,000
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.05 $25,404 - $30,660	29,200 Added 154.5%	48,100 $42,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.26 $11,193 - $15,498	12,300 Added 186.36%	18,900 $20,000
Q4 2023 Feb 14, 2024	BUY	$0.9 - $1.06 $1,530 - $1,802	1,700 Added 34.69%	6,600 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.94 - $1.23 $7,520 - $9,840	-8,000 Reduced 62.02%	4,900 $4,000
Q2 2023 Aug 14, 2023	SELL	$1.1 - $1.54 $16,720 - $23,408	-15,200 Reduced 54.09%	12,900 $15,000
Q1 2023 May 15, 2023	SELL	$1.19 - $2.09 $15,827 - $27,796	-13,300 Reduced 32.13%	28,100 $35,000
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.35 $45,925 - $64,625	27,500 Added 197.84%	41,400 $77,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $2.76 $7,421 - $11,316	-4,100 Reduced 22.78%	13,900 $27,000

37M

52.7K

130K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $77.1M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.